Liver Metastases Treatment Global Market Report 2024

The liver metastases treatment market size has grown strongly in recent years. It will grow from $1.45 billion in 2023 to $1.57 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the expansion of personalized medicine, increased access to healthcare services, improved multidisciplinary care approaches, and the proliferation of clinical trials and research initiatives.

The liver metastases treatment market size is expected to see strong growth in the next few years. It will grow to $2.19 billion in 2028 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to the adoption of patient-centric care models, the advancement of precision medicine approaches, the shift towards outpatient and ambulatory care settings, and regulatory initiatives aimed at improving healthcare outcomes. Major trends expected during the forecast period include the adoption of next-generation sequencing technologies, advancements in immuno-oncology, the emergence of liquid biopsy technologies, and the utilization of adjuvant therapies.

The increasing incidence of liver disease is anticipated to drive the expansion of the liver metastases treatment market in the foreseeable future. Liver disease encompasses various disorders that impair the liver's function, posing risks to overall health and bodily functions such as metabolism and detoxification. Treatments for liver metastases play a critical role in preserving liver function and overall wellness. In many cases, comprehensive treatments involving surgical resection, ablation techniques, or targeted therapies are necessary for achieving long-term remission, often complemented by systemic medications such as chemotherapy or immunotherapy. For example, Cancer Australia reported approximately 2,905 new cases of liver cancer diagnosed in Australia in 2022, indicating a significant burden of the disease. The predicted risk of developing liver cancer by age 85 underscores the importance of addressing liver disease effectively. Thus, the increasing prevalence of liver disease acts as a key driver for the liver metastases treatment market.

Leading companies in the liver metastases treatment market are focused on introducing liver-directed therapies to provide effective and convenient treatment options. Liver-directed therapies specifically target liver-related diseases or conditions, aiding in the management of liver metastases by directly targeting cancerous cells within the liver. These therapies encompass various approaches, including surgical resection, radiofrequency ablation, transarterial chemoembolization, radioembolization, and stereotactic body radiation therapy. For instance, Delcath Systems Incorporated launched the Hepzato kit in August 2023, a liver-directed treatment for adult patients with metastatic uveal melanoma affecting less than 50% of the liver. The kit delivers melphalan, a chemotherapeutic agent, directly to the liver through Delcath's Hepatic Delivery System, offering targeted treatment while minimizing systemic toxicity.

In August 2023, TriSalus Life Sciences completed its merger with MedTech Acquisition Corporation, underscoring its commitment to advancing innovative treatments for liver and pancreatic tumors. TriSalus Life Sciences specializes in developing proprietary delivery technologies that enable precise and targeted delivery of immunotherapy agents directly to tumor sites, maximizing therapeutic efficacy while minimizing systemic side effects. The merger with MedTech Acquisition Corporation, a blank check company, signifies a strategic move aimed at accelerating the development and commercialization of novel treatments for liver and pancreatic tumors.

Major companies operating in the liver metastases treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, Bristol Myers Squibb, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Gilead Sciences Inc., Takeda Pharmaceutical Company, Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Eisai Co. Ltd., Incyte Corporation, Ipsen, Seattle Genetics, Exelixis Inc., Array BioPharma Inc., Genentech Inc., Clovis Oncology, Agios Pharmaceuticals Inc., Taiho Pharmaceutical Co.Ltd.

North America was the largest region in the liver metastases treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver metastases treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the liver metastases treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Liver metastases treatment involves therapeutic interventions targeted at managing cancerous growths that have spread to the liver from primary tumors elsewhere in the body. This comprehensive treatment strategy aims to improve patient outcomes by shrinking or eliminating metastatic lesions, alleviating symptoms, and enhancing overall quality of life.

The main types of liver metastases treatment include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy is a cancer treatment approach that utilizes drugs to destroy cancer cells. It is employed for treating liver metastasis resulting from various primary cancers such as colorectal cancer and breast cancer. Chemotherapy drugs are distributed through various channels including hospital pharmacies and specialty pharmacies.

The liver metastasis treatment market research report is one of a series of new reports that provides liver metastasis treatment market statistics, including liver metastasis treatment industry global market size, regional shares, competitors with a liver metastasis treatment market share, detailed liver metastasis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the liver metastasis treatment industry. This liver metastasis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver metastases treatment market consists of revenues earned by entities by providing services such as surgery, radiotherapy, palliative care, diagnostic imaging, biopsy, ablation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver metastases treatment market also includes sales of therasphere, sir-spheres gamma-90 resin microspheres, Avastin, Nexavar, Keytruda, radiofrequency ablation devices, and cyberknife. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.